Literature DB >> 32471266

Monitoring Insecticide Susceptibility in Aedes Aegypti Populations from the Two Biggest Cities, Ouagadougou and Bobo-Dioulasso, in Burkina Faso: Implication of Metabolic Resistance.

Moussa Namountougou1,2,3, Dieudonné Diloma Soma1,2,3, Mahamoudou Balboné4, Didier Alexandre Kaboré1,2, Mahamadi Kientega1,2, Aristide Hien1,2, Ahmed Coulibaly5, Parfait Eric Ouattara1,2, Benson Georges Meda1,2, Samuel Drabo4, Lassane Koala1,2, Charles Nignan1,2, Thérèse Kagoné2, Abdoulaye Diabaté1,2, Florence Fournet6, Olivier Gnankiné4, Roch Kounbobr Dabiré1,2.   

Abstract

In West Africa, Aedes aegypti remains the major vector of dengue virus. Since 2013, dengue fever has been reemerging in Burkina Faso with annual outbreaks, thus becoming a major public health problem. Its control relies on vector control, which is unfortunately facing the problem of insecticide resistance. At the time of this study, although data on phenotypic resistance were available, information related to the metabolic resistance in Aedes populations from Burkina Faso remained very scarce. Here, we assessed the phenotypic and the metabolic resistance of Ae. aegypti populations sampled from the two main urban areas (Ouagadougou and Bobo-Dioulasso) of Burkina Faso. Insecticide susceptibility bioassays to chlorpyriphos-methyl 0.4%, bendiocarb 0.1% and deltamethrin 0.05% were performed on natural populations of Ae. aegypti using the WHO protocol. The activity of enzymes involved in the rapid detoxification of insecticides, especially non-specific esterases, oxidases (cytochrome P450) and glutathione-S-transferases, was measured on individual mosquitos. The mortality rates for deltamethrin 0.05% were low and ranged from 20.72% to 89.62% in the Bobo-Dioulasso and Ouagadougou sites, respectively. When bendiocarb 0.1% was tested, the mortality rates ranged from 7.73% to 71.23%. Interestingly, in the two urban areas, mosquitoes were found to be fully susceptible to chlorpyriphos-methyl 0.4%. Elevated activity of non-specific esterases and glutathione-S-transferases was reported, suggesting multiple resistance mechanisms involved in Ae. aegypti populations from Bobo-Dioulasso and Ouagadougou (including cytochrome P450). This update to the insecticide resistance status within Ae. aegypti populations in the two biggest cities is important to better plan dengue vectors control in the country and provides valuable information for improving vector control strategies in Burkina Faso, West Africa.

Entities:  

Keywords:  Aedes aegypti; Burkina Faso; Dengue; Insecticide susceptibility; Metabolic Resistance

Year:  2020        PMID: 32471266     DOI: 10.3390/tropicalmed5020084

Source DB:  PubMed          Journal:  Trop Med Infect Dis        ISSN: 2414-6366


  4 in total

1.  Review of the ecology and behaviour of Aedes aegypti and Aedes albopictus in Western Africa and implications for vector control.

Authors:  Beatrice R Egid; Mamadou Coulibaly; Samuel Kweku Dadzie; Basile Kamgang; Philip J McCall; Luigi Sedda; Kobie Hyacinthe Toe; Anne L Wilson
Journal:  Curr Res Parasitol Vector Borne Dis       Date:  2022

2.  Spatiotemporal distribution and insecticide resistance status of Aedes aegypti in Ghana.

Authors:  Christopher M Owusu-Asenso; Julius A A Mingle; David Weetman; Yaw A Afrane
Journal:  Parasit Vectors       Date:  2022-02-19       Impact factor: 3.876

3.  Temporal Evaluation of Insecticide Resistance in Populations of the Major Arboviral Vector Aedes Aegypti from Northern Nigeria.

Authors:  Muhammad M Mukhtar; Sulaiman S Ibrahim
Journal:  Insects       Date:  2022-02-10       Impact factor: 2.769

4.  Analyses of Insecticide Resistance Genes in Aedes aegypti and Aedes albopictus Mosquito Populations from Cameroon.

Authors:  Borel Djiappi-Tchamen; Mariette Stella Nana-Ndjangwo; Konstantinos Mavridis; Abdou Talipouo; Elysée Nchoutpouen; Idene Makoudjou; Roland Bamou; Audrey Marie Paul Mayi; Parfait Awono-Ambene; Timoléon Tchuinkam; John Vontas; Christophe Antonio-Nkondjio
Journal:  Genes (Basel)       Date:  2021-05-28       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.